Merck (MRK) said Tuesday it has received conditional approval from the European Commission for its Welireg drug to treat adult patients with von Hippel-Lindau disease, a rare genetic disorder characterized by the formation of tumors and cysts in certain parts of the body.
Welireg is for those patients with von Hippel-Lindau disease who require therapy for renal cell carcinoma, central nervous system hemangioblastomas or pancreatic neuroendocrine tumors, and for whom localized procedures are unsuitable. The drug is also for those with previously treated advanced renal cell carcinoma, the company said.
Welireg can now be marketed in all 27 European Union member states, as well as Iceland, Liechtenstein, and Norway. The conditional approval of the drug is valid for one year and is subject to yearly renewal, pending additional data from two of Merck's ongoing clinical trials, the company said.
Price: 82.28, Change: -0.73, Percent Change: -0.88
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。